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A Review of Guidelines And APPRoAcHes to PeRfoRmAnce-BAsed Risk-
sHARinG AGReements AcRoss tHe uk, itAly And tHe netHeRlAnds
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Abacus International, Manchester, UK
Objectives: In response to greater health budget restrictions and the rise in costly 
new treatments, manufacturers and payers have increasing interest in performance-
based risk-sharing arrangements (PBRSAs) that address uncertainty and accelerate 
access to medicines. Our objectives were to review guidelines for PBRSA implemen-
tation and the use of PBRSAs in the UK, Italy, and the Netherlands. MethOds: 
A non-systematic review was undertaken using PubMed to identify guidance on 
PBRSA implementation. Appropriate governmental and agency websites in the UK, 
Italy, and the Netherlands were also reviewed to identify PBRSA examples. Key 
considerations for PBRSA implementation and its historical application in the UK, 
Italy and the Netherlands were evaluated. Results: Several key considerations for 
PBRSA implementation were identified from published guidelines. The approach to 
PBRSA implementation varies between countries with regards to: evidence collec-
tion, governance, reporting, and evaluation. While PBRSAs have been applied in the 
UK, simple cost-sharing arrangements are now encouraged due to difficulties with 
the implementation and evaluation of PBRSAs. In Italy, AIFA makes extensive use of 
online monitoring registries to inform their PBRSAs. However, there is no established 
process for implementation. Currently, in the Netherlands all inpatient drugs with a 
budget impact > € 0.6 million and an unacceptable level of uncertainty can be granted 
access via coverage with evidence development arrangements. Both national and 
international registry data are used in the re-evaluation of reimbursement deci-
sions. cOnclusiOns: The approach to PBRSA implementation varied across the 
three countries reviewed, although the objectives for their use were similar across 
the analysed countries. Manufacturers need to consider country-specific factors 
for implementation and key PBRSA considerations identified via our research offer 
guidance for applying PBRSAs in these markets.
PHP313
wHicH Risk sHARe AGReements ARe AvAilABle And ARe tHose APPlied in 
GloBAl ReimBuRsement decisions?
Walzer S1, Droeschel D1, Shannon R2
1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2Global Health 
Economic Projects, LLC, New York, NY, USA
Objectives: Risk Share Agreements (RSAs) are defined as agreements between 
a payer and a manufacturer where the price level is related to the actual future 
performance of the product. In the last years RSAs were introduced and applied in 
various jurisdictions. MethOds: RSAs in Australia, Canada, Italy, Spain, UK and the 
US were systematically searched for. They were clustered into the type of RSA per 
country and compared to each other. Results: In Australia the main RSA types 
were annual sales caps, indication-wide caps, label caps, price-volume agreements, 
comparator rebates. The details of deeds of agreements/RSAs are generally not 
publicly available. In Canada the final formulary inclusion decisions are made by 
each province separately where confidential contracting with direct discounts are 
preferred. In Italy different contracting mechanisms evolved to payments-by-results 
in the last years with the AIFA patient registry supporting the implementation of 
RSAs. Even though payment-by-results was the main type of RSA, cost sharing, cost 
ceiling, risk sharing and combination types were accepted. In Spain contracting 
has become relevant with the introduction of dual pricing (list price vs reimbursed 
price). Combination RSA types (rebates, price-volume agreements, utilization cap, 
therapeutic positioning, pay-for-performance) were used at all levels whereas most 
regions have discount/rebate volume-based negotiations at hospital levels for high 
budget impact drugs. In the UK many recently launched high cost drugs achieved 
positive NICE guidance only if a patient access scheme was offered; with discount 
“only” schemes as the only one accepted by the NHS. In the US RSA are differently 
used to other markets mainly as coverage with evidence development type and not 
directly linked to the actual price. cOnclusiOns: Currently RSAs are applied in 
different countries, however not in the same way and utilizing the same types for 
RSA with discounts as being the most relevant for payers.
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Objectives: To understand opinions and attitudes on whether and why managed 
entry agreements (MEAs) are needed in today’s healthcare systems, and what can 
make them work. MethOds: Representatives from pharmaceutical companies 
(n= 9) were interviewed, including personnel from pricing, market access, health 
economics and outcomes research and marketing. Payer proxies from the UK, Italy, 
France and Spain, such as health economists and payer advisors (n= 10), were also 
interviewed. Results: Industry stakeholders largely perceived MEAs as a tactical 
means to accelerate market access for premium-priced, specialised medicines - with 
a view to reduce budget impact and/or uncertainty of the clinical benefits; the focus 
depends on the characteristics of the drug and the country. Often, a confidential 
straight discount is preferred. Addressing the uncertainty about clinical benefits was a 
particularly important concern in oncology. The payer proxies typically viewed MEAs 
as instruments to reduce the drug’s budget impact. An important success factor was 
the payers’ motivation to grant access to the novel therapy and view MEAs as appro-
priate to enable it. This means that the MEA should be transparent and simple in its 
framework. Since various stakeholders in the healthcare system are involved, an 
MEA should address their specific incentives. In principle, involving payers during 
the development of an MEA concept could increase its chance of success, but this 
rarely occurs. Several industry respondents identified factors within the company 
as critical e.g. insufficient capabilities, poor coordination in the decision making. 
Country-specific/local constraints play a major role in the feasibility and success of 
MEA implementation. An important limitation is the availability of an appropriate 
the population, with more population groups covered with all three levels of care; 
primary, secondary and tertiary. However, informal sector, the most challenging 
sector worldwide, is not covered through HIO. HIO acts as both service purchaser 
and provider through a widely distributed owned health facilities, in addition to 
outsourcing some secondary and tertiary care services. With the government’s 
plan to implement universal health coverage (UHC) by 2030, HIO is considered 
as the strategic future national purchaser, especially with HIO long experience, 
covering more than half of the population. However, HIO needs to acknowledge 
its structural and operational challenges, and address them, in order to be able 
to carry on this responsibility of being the nation’s health insurer. Objectives: 
This paper discusses the capabilities of the current HIO, highlighting its strengths 
and challenges that need to be addressed before being able to be the sole health 
services purchaser in Egypt. MethOds: A qualitative study, using information 
from the literature and official government documents, describing the laws and 
regulations that govern the work of HIO. It also provides insights into some of the 
foreseen challenges from a health system perspective, discussing challenges to 
be faced by HIO, and other stakeholders like private health insurance and phar-
maceutical companies. It will also provide recommendations on how to overcome 
some of these challenges in the future. Results: Allignment between different 
stakeholders; e.g. government, pharma and healthcare professionals is a must 
to achieve UHC in Egypt. cOnclusiOns: HIO is the strategic national payer in 
Egypt, but this requires structural and operational reform, so that its objective 
of UHC.
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Objectives: Medical registers are recognized as an important tool in health ser-
vices research (HSR) and health technology assessment (HTA). However, optimal 
use remains to be defined. In 2011, the Swiss Medical Association (FMH) launched a 
project to systematically list all medical registers in Switzerland to improve trans-
parency and networking. This interim analysis shows the current state, potential 
weaknesses and needs for action. MethOds: This prospective study analyzed 
function, classification (epidemiological/clinical) and current status of all Swiss 
medical registers listed on the FMH database. We integrated purpose and proper-
ties by a self-developed typology. Based on our findings, we describe current state 
and suggest new directions. Results: 33 registers were classified as clinical, 36 as 
epidemiological, and 4 as “other”. 66 (90%) were active. The purpose of the registers 
(epidemiological surveillance, quality management, prioritization, HTA) was often 
not specified 28 registers were run by a university (14 clinical, 12 epidemiological, 
2 ”other”),35 (10/23/2) by a public institution, 10 (9/1/0) by a commercial company. 
Clinical registers have the highest probability to be run by a commercial company 
(RR= 2.36;[CI: 1.62-3.44]. 37 registers were national (18/ 18/1), 60 national andin-
ternational (82%;33/24/3) and 13 local (0/12/1). 30 registers (41%) were manda-
tory with no significant differences between the different types. 4 registers were 
linked to HTA decision making. There was an overlap in 4 trauma registers and 
we identified registers that are not listed in the FMH database. Only 6 clinical 
registers have an auditing system in place (9%; 95%-CI 2-14;), none a standard-
ized quality management system. cOnclusiOns: There is documented goodwill 
to conduct medical registers in Switzerland, and to make them available to the 
medical community, to HTA and HSR.There appears a need for a quality manage-
ment system and supervision at a higher level to safeguard quality standards and 
transparency.
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Objectives: The increasing prevalence of obesity, which is associated with physi-
cal inactivity and sedentary lifestyle, continues to increase and pose a substantial 
economic burden in most developed countries. Many workplace wellness programs 
have evolved to integrate the use of financial incentives to promote behaviour 
change and healthier lifestyles. The purpose of the present study was to deter-
mine whether tournament-style financial incentive (individual-level competitive 
prize of S$150) was effective in motivating adults in the workplace to increase 
daily stair usage over a 6-week period between July and October 2014. This study 
incorporates behavioural economic principles, a workplace stairs competition and 
point-of-decision prompts to offer insights on a behavioural reinforcement strategy 
on physical activity. MethOds: Participants (N= 41) were randomized to one of the 
two experimental groups: (i) control group without financial incentives (n= 20) or 
(ii) intervention group with financial incentives (n= 21). Data was collected using a 
self-monitoring steps cum calories tracker app installed into mobile devices of par-
ticipants in both groups. Results: The intervention group significantly increased 
their stair use compared to the control group by a difference of 7,743 steps (95% CI: 
2,889 – 12,598, p= 0.003). Furthermore, participants in the financial incentive inter-
vention group burned 579 more calories, on average, than the control group (95% 
CI: 229 – 930, p= 0.002). There was no sustained significant effect beyond the 6-week 
period of intervention. cOnclusiOns: Participants in the financial incentive inter-
vention group outperformed the control group through increased stair usage, and 
hence physical activity levels. There is evidence that the use of tournament-style 
financial incentives can promote the uptake of physical activity, however this effect 
attenuates over time and is not sustained beyond the period of intervention. Further 
research should be broadened to include investigating novel mHealth technologies 
that increase stair use and multicomponent interventions that promote physical 
activity for a sustained period of time.
